Basic information Safety Supplier Related

C188-9

Basic information Safety Supplier Related

C188-9 Basic information

Product Name:
C188-9
Synonyms:
  • C188-9
  • C 188-9;C-188-9;C-1889;C1889;C 1889;C-1889;F0808-0084
  • N-(1',2-dihydroxy-1.2'-binaphthhalen-4'-yl)-4-methoxybenzene-sulphonamide
  • C188-9; C 188-9; C-188-9; C-1889; C1889; C 1889; C-1889; F0808-0084
  • F0808-0084
  • TTI-101
  • Benzenesulfonamide, N-(1',2-dihydroxy[1,2'-binaphthalen]-4'-yl)-4-methoxy-
  • N-(1',2-Dihydroxy-[1,2'-binaphthalen]-4'-yl)-4-methoxybenzenesulfonamide
CAS:
432001-19-9
MF:
C27H21NO5S
MW:
471.52
Mol File:
432001-19-9.mol
More
Less

C188-9 Chemical Properties

Boiling point:
680.9±65.0 °C(Predicted)
Density 
1.416±0.06 g/cm3(Predicted)
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2) (1:5): 0.16 mg/ml
form 
A crystalline solid
pka
8.14±0.50(Predicted)
color 
Off-white to pink
More
Less

C188-9 Usage And Synthesis

Uses

C188-9 (TTI-101) is a STAT3 inhibitor, with a Kd of 4.7 nM. C188-9 inhibits G-CSF-induced STAT3 activation and STAT3-dependent gene expression. C188-9 induces apoptosis in AML cell lines and primary samples and inhibits colony formation by primary AML blasts[1][2][3][4].

Biological Activity

C188-9 (TTI 101) is a potent STAT3 inhibitor, binds STAT3 with high affinity, Kd=4.7±0.4 nM. It is well tolerated in mice, has good oral bioavailability, and is mainly enriched in tumor tissues.

in vitro

C188-9 is a small molecule inhibitor of STAT3, targeting the phosphotyrosine peptide binding site in the SH2 region of STAT3 with a Ki value of 136 nM. It does not inhibit upstream Jak or Src kinases.

in vivo

C188-9 inhibited tumor growth in mice bearing UM-SCC-17B xenografts after administration of C188-9. C188-9 was well tolerated in mice, had good oral bioavailability, and was concentrated in tumor tissue after administration.

target

TargetValue
STAT3
(Cell-free)
4.7 nM(Kd)

IC 50

STAT3: 4.7 nM (Kd)

References

[1] Silva KA, et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 2015 Apr 24;290(17):11177-87. DOI:10.1074/jbc.M115.641514
[2] Redell MS, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011 May 26;117(21):5701-9. DOI:10.1182/blood-2010-04-280123
[3] Bharadwaj U, et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 3;7(18):26307-30. DOI:10.18632/oncotarget.8368
[4] Redell MS, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701-5709. DOI:10.1182/blood-2010-04-280123

C188-9Supplier

WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 18971495150;
Email
sales@sun-shinechem.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Email
product02@bidepharm.com
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn